T-cell LymphomaNCT05978141
A Registry for People With T-cell Lymphoma
An observational study of T-cell Lymphoma and NK-Cell Lymphoma, run by Memorial Sloan Kettering Cancer Center at 26 sites in United States.
Trial summary
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia
- What is being tested?
- Optional Blood Sample and Nail Sample
- How many people
- 1,000 participants
- Where
- 26 sitesUnited States
- Study dates
- 27 Jul 2023to 27 Jul 2030
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Participants at Memorial Sloan Kettering Cancer Center (MSKCC) will be recruited through the Lymphoma service in the Department of Medicine and the Department of Pediatrics. Participants will be recruited at the participating centers.
Who may be able to join
- Written informed consent
- Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
- Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
Show all 32Show fewer
- Aggressive NK-cell leukemia
- Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
- Chronic active EBV infection of T- and NK-cell type, systemic form
- Hydroa vacciniforme-like lymphoproliferative disorder
- Adult T-cell leukemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Intestinal T-cell lymphoma, not otherwise specified (NOS)
- Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
- Sézary syndrome
- Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
- Primary cutaneous Gamma-Delta T-cell lymphoma
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
- Peripheral T-cell lymphoma, not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Follicular T-cell lymphoma
- Nodal peripheral T-cell lymphoma with TFH phenotype
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Breast-implant associated anaplastic large cell lymphoma.
- NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
Who cannot join
- Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
- Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
Trial locations and contacts
26 sites in 1 country. Contact the study team or a site near you to ask about taking part.
26 sites in 1 country
United States26 sites, 26 recruiting
- Not yet recruiting
Emory University (Data Collection Only)
Atlanta, Georgia, 30322
Pamela Allen, MD, MSc, 404-778-0519
- Not yet recruiting
University of Colorado (Data Collection Only)
Aurora, Colorado, 80045
Bradley Haverkos, MD, 212-639-3983
- Recruiting
Memorial Sloan Kettering at Basking Ridge (All protocol activities)
Basking Ridge, New Jersey, 07920
Steven Horwitz, MD, 646-608-2680
- Not yet recruiting
Massachusetts General Hospital (Data Collection Only)
Boston, Massachusetts, 02114
Salvia Jain, MD, 857-392-4495
- Not yet recruiting
Dana Farber Cancer Institute (Data Collection Only)
Boston, Massachusetts, 02115
Eric D Jacobsen, MD, 877-442-3324
- Not yet recruiting
Northwestern Medicine (Data Collection)
Chicago, Illinois, 60611
Jaehyuk Choi, MD, PhD, 312-695-8106
- Not yet recruiting
Ohio State University (Data Collection Only)
Columbus, Ohio, 43210
John Reneau, MD, PhD, 614-293-8000
- Recruiting
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)
Commack, New York, 11725
Steven Horwitz, MD, 646-608-2680
- Not yet recruiting
City of Hope Cancer Center (Data collection only)
Duarte, California, 91010
Jasmine Zain, MD, 626-359-8111
- Recruiting
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York, 10604
Steven Horwitz, MD, 646-608-2680
- Not yet recruiting
MD Anderson Cancer Center (Data Collection Only)
Houston, Texas, 77030
Swami Iyer, MD, 713-352-2952
- Not yet recruiting
University of Miami (Data Collection Only)
Miami, Florida, 33136
Jonathan Schatz, MD, 305-243-5302
- Recruiting
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748
Steven Horwitz, MD, 646-608-2680
- Not yet recruiting
Yale University (Data Collection Only)
New Haven, Connecticut, 06511
Francine Foss, MD, 203-200-4363
- Not yet recruiting
Weill Cornell Medical Center (Data Collection Only)
New York, New York, 10021
Jia Ruan, MD, PhD, 646-962-2064
- Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
Steven Horwitz, MD, 646-608-2680
- Not yet recruiting
University of Nebraska (Data collection only)
Omaha, Nebraska, 68198-7680
Matthew Lunning, DO, FACP, 402-559-4000
- Not yet recruiting
University of Pennsylvania (Data Collection Only)
Philadelphia, Pennsylvania, 19104
Stefan Barta, MD, MS, MRCPCUK, (215) 316-5151
- Not yet recruiting
Thomas Jefferson University Hospital (Data collection only)
Philadelphia, Pennsylvania, 19107
Pierluigi Porcu, MD, 215-955-8874
- Not yet recruiting
Mayo Clinic (Data Collection Only)
Rochester, Minnesota, 55905
Nora Bennani, MD, 507-284-2511
- Not yet recruiting
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)
San Diego, California, 92103
Aaron Goodman, MD, 858-822-6100
- Not yet recruiting
University of California San Francisco (Data collection only)
San Francisco, California, 94143
Weiyun Ai, MD, 415-353-2421
- Not yet recruiting
Washington University (Data Collection Only)
St Louis, Missouri, 63110
Neha Mehta-Shah, MD, MSCI, 314-747-1171
- Not yet recruiting
Stanford University Medical Center (Data collection only)
Stanford, California, 94305-5408
Michael Khodadoust, MD, 650-725-5071
- Not yet recruiting
Moffitt Cancer Center (Data Collection Only)
Tampa, Florida, 33612
Lubomir Sokol, MD, PhD, 888-663-3488
- Recruiting
Memorial Sloan Kettering Nassau (All protocol activities)
Uniondale, New York, 11553
Steven Horwitz, MD, 646-608-2680
About this study
Official title: The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia
- Being tested
- Optional Blood Sample and Nail Sample
- Keywords
- 23-190, T-cell lymphoma, Memorial Sloan Kettering Cancer Center, T-cell Lymphoma Master Repository, TCLMR
- Medical subject headings
- Lymphoma, T-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma, Subcutaneous panniculitis-like T-cell lymphoma, Mycosis Fungoides
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optional Blood Sample and Nail SampleOther
Participants may provide optional research blood and nail samples for biobanking and future use
| Study group | Role | What they receive |
|---|---|---|
| Participants with T-Cell Lymphoma | Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma Receives: Other: Optional Blood Sample and Nail Sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants populating the T-cell Lymphoma Master Repository/TCLMR
To develop and populate a secure database comprised of patients with T-cell lymphomas with curated clinical characteristics and treatment outcomes matched to pathological biospecimens.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2023
- Study start27 Jul 2023
- Primary completion27 Jul 2030 (estimated)
- Study completion27 Jul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for T-cell LymphomaStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Steven Horwitz, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05978141
- Sponsor's protocol ID
- 23-190
- Status last verified
- May 2026
- First submitted
- 28 Jul 2023
- Last updated
- 20 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.